Ortho Clinical Diagnostics announced commercial availability in Europe for two new clinical laboratory systems, the flagship Vitros 5600 Integrated System and the high-capacity Vitros 3600 Immunodiagnostic System. These next generation diagnostic platforms are uniquely designed based on world-class Vitros technologies to address the needs of the modern clinical laboratory, giving patients and clinicians high-quality and reliable test results.

Workflow data and input from 60 clinical laboratories worldwide drove the innovative designs of the Vitros 5600 and 3600 Systems. Both instruments incorporate proven Vitros technologies and use the same reagents as other Vitros platforms thereby maintaining the same degree of accuracy. The compact systems do not have any water or drainage requirements, making the most of limited lab space while allowing flexibility in instrument location.

"Our mission has always been to give health professionals the highest quality tools to determine the best treatment. The introduction of the Vitros 5600 Integrated System and Vitros 3600 Immunodiagnostic System continues this mission with next generation instruments that have a broad, world class menu of assays and the capacity to support future high-impact tests," said David Atkins, vice president for Ortho Clinical Diagnostics, EMEA. "Ortho Clinical Diagnostics is committed to developing advanced medical tests through our investment in specific disease-state biomarkers in reproductive health, oncology, cardiology and metabolic diseases."

The Vitros 5600 System is designed to integrate clinical chemistry and immunoassay testing to increase laboratory productivity and can perform more than 100 different chemistry, immunoassay and infectious disease assays on a single, high- quality system.

Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers the high quality in-vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner.